B. Tweedy, Ch. Browne
Tweedy, Browne Co All Funds (US)
Tweedy, Browne Co All Funds (US) Ionis Pharmaceuticals Inc stake
total: 174
Tweedy, Browne Co All Funds (US) IONS trades
- Total transactions:
- 14
- New positions:
- 1
- Added:
- 2
- Reduced:
- 11
- Held since:
- 2022 Q1
- Held for:
- 17 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Tweedy, Browne Co All Funds (US) holds 2,275,625 Ionis Pharmaceuticals Inc (IONS) shares with a market value of roughly $170.88M accounting for 13.57% of the overall portfolio. To date, the estimated cost basis is nearly $37.27 for "buy" trades and estimated average "sell" price is $53.67. Tweedy, Browne Co All Funds (US) first purchased IONS in 2022 Q1, initially acquiring about 2.93M shares. Since the initial investment in Ionis Pharmaceuticals Inc (IONS), Tweedy, Browne Co All Funds (US) has made 13 more transactions.
When did Tweedy, Browne Co All Funds (US) buy Ionis Pharmaceuticals Inc (IONS)?
Tweedy, Browne Co All Funds (US) first invested in Ionis Pharmaceuticals Inc (IONS) in 2022 Q1 at the reported quarter-end price of $37.04 per share.
What's the cost basis of Tweedy, Browne Co All Funds (US)'s IONS stake?
The estimated cost basis for Ionis Pharmaceuticals Inc (IONS) stake is around $37.27 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $37.27
- Weighted AVG sell price:
- $53.67
Tweedy, Browne Co All Funds (US)'s historical trades in Ionis Pharmaceuticals Inc
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
13.57%
|
2,275,625
|
$75.09
|
$170,876,681
|
-7.68% (-189,305)
|
-1.15%
|
|
2025 Q4
|
15.74%
|
2,464,930
|
$79.11
|
$195,000,612
|
-15.04% (-436,286)
|
-3%
|
|
2025 Q3
|
16.48%
|
2,901,216
|
$65.42
|
$189,797,551
|
+0.32% (+9,268)
|
+0.05%
|
|
2025 Q2
|
10.60%
|
2,891,948
|
$39.51
|
$114,260,865
|
-3.07% (-91,570)
|
-0.32%
|
|
2025 Q1
|
7.98%
|
2,983,518
|
$30.17
|
$90,012,738
|
-8.17% (-265,345)
|
-0.54%
|
|
2024 Q4
|
7.66%
|
3,248,863
|
$34.96
|
$113,580,250
|
-5.96% (-205,813)
|
-0.34%
|
|
2023 Q4
|
8.53%
|
3,454,676
|
$50.59
|
$174,772,059
|
-1.58% (-55,497)
|
-0.15%
|
|
2023 Q3
|
8.52%
|
3,510,173
|
$45.36
|
$159,221,447
|
-0.87% (-30,685)
|
-0.07%
|
|
2023 Q2
|
7.63%
|
3,540,858
|
$41.03
|
$145,281,000
|
-0.01% (-188)
|
-0%
|
|
2023 Q1
|
6.89%
|
3,541,046
|
$35.74
|
$126,557,000
|
-0.00% (-90)
|
-0%
|
|
2022 Q4
|
7.12%
|
$37.77
|
+30.05% (+818,148)
|
|||
|
2022 Q3
|
5.30%
|
$44.23
|
-0.14% (-3,790)
|
|||
|
2022 Q2
|
4.13%
|
$37.02
|
-6.78% (-198,324)
|
|||
|
2022 Q1
|
3.50%
|
$37.04
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.